A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure
Latest Information Update: 12 Aug 2022
Price :
$35 *
At a glance
- Drugs TRV 027 (Primary)
- Indications Acute heart failure; Decompensated heart failure
- Focus Therapeutic Use
- Acronyms BLAST-AHF
- Sponsors Trevena
- 03 Aug 2022 Results assessing the role of NLR in predicting cardiovascular outcomes in patients with acute heart failure from BLAST-AHF, Pre-RELAX-AHF & RELAX-AHF, published in the American Journal of Cardiology.
- 23 Oct 2019 Results of secondary analysis of BLAST-AHF trial, published in the European Journal of Heart Failure.
- 14 Nov 2018 Results of secondary analysis presented at the 91st Annual Scientific Sessions of the American Heart Association